Ackrell Capital Cannabis Investment Report outlines FDA regulatory stance on THC/CBD foods and supplements

Ackrell Capital Cannabis Investment Report outlines FDA regulatory stance on THC/CBD foods and supplements The passage provides a summary of FDA guidance and regulatory framework for cannabis-derived products, but it contains no specific allegations, names, transactions, or actionable leads involving high‑profile individuals or agencies. It is largely a policy overview, offering limited investigative value beyond general regulatory context. Key insights: FDA guidance (Aug 2017) states THC/CBD cannot be added to foods sold interstate and are not dietary supplements.; Regulatory ambiguity remains for hemp‑derived CBD products.; DEA announced a policy to increase registered cannabis cultivators for drug development.